Title: Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.

Authors: Hoque, Ashraful; Ambrosone, Christine B; Till, Cathee; Goodman, Phyllis J; Tangen, Cathy; Kristal, Alan; Lucia, Scott; Wang, Qiao; Kappil, Maya; Thompson, Ian; Hsing, Ann W; Parnes, Howard; Santella, Regina M

Published In Cancer Prev Res (Phila), (2010 Apr)

Abstract: To evaluate the role of oxidative stress in prostate cancer risk, we analyzed serum levels of protein carbonyl groups in 1,808 prostate cancer cases and 1,805 controls, nested in the Prostate Cancer Prevention Trial, a randomized, placebo-controlled trial that found finasteride decreased prostate cancer risk. There were no significant differences in protein carbonyl levels in baseline samples between those later diagnosed with prostate cancer and those without at the end of study biopsy. Adjusted odds ratios and 95% confidence intervals (95% CI) for the 4th quartile of protein carbonyl level for the combined, placebo, and finasteride arms were 1.03 (95% CI, 0.85-1.24), 0.88 (95% CI, 0.69-1.12), and 1.27 (95% CI, 0.94-1.71), respectively. There were no significant associations between carbonyl level and risk when analyzing high-grade and low-grade disease separately, nor did finasteride affect protein oxidation levels. The results of this large nested case-control study do not support the hypothesis that oxidative stress, at least as measured by protein carbonyl level, plays a role in prostate cancer.

PubMed ID: 20332306

MeSH Terms: Case-Control Studies; Double-Blind Method; Enzyme Inhibitors/therapeutic use*; Enzyme-Linked Immunosorbent Assay; Finasteride/therapeutic use*; Humans; Male; Middle Aged; Oxidative Stress/physiology*; Prostatic Neoplasms/blood*; Prostatic Neoplasms/pathology; Prostatic Neoplasms/prevention & control*; Protein Carbonylation/drug effects*; Protein Carbonylation/physiology; Risk Factors